# Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

> **NCT04500431** · PHASE1 · UNKNOWN · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Targeting CD269 chimeric antigen receptor engineered T cells

## Key facts

- **NCT ID:** NCT04500431
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04500431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04500431, "Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04500431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*